Annovis’ Buntanetap in PD faces complex road ahead despite phase III progress, says GlobalData
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
Subscribe To Our Newsletter & Stay Updated